Active monitoring after chemo-radiation plus immunotherapy for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new approach for people with a certain type of esophageal cancer. Instead of surgery right away, you would receive chemotherapy, radiation, and an immunotherapy drug called adebrelimab. After that, doctors will closely watch your cancer to see if it's gone. The goal is to avoid surgery if the treatment works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma (confirmed by biopsy).
- Your cancer is in the middle or lower part of the esophagus and is stage II or III (but not spread to other organs).
- You are between 18 and 75 years old.
- You are healthy enough for daily activities (ECOG score 0–1).
- You have not had any previous cancer treatments like chemotherapy, radiation, or surgery for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This trial tests a drug called adebrelimab (an immunotherapy) combined with chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery or has come back after surgery. It aims to see if the combination is safe and effective.
This trial tests a combination of immunotherapy (adebrelimab) plus standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if adding the immunotherapy before and during chemoradiation helps control the cancer better.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
This trial tests a combination of immunotherapy (adebrelimab) and two chemotherapy drugs before surgery for patients with advanced but removable esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This Phase 2 study tests whether adding an immunotherapy drug (camrelizumab) to standard chemo-radiation can help some people with operable esophagus cancer avoid immediate surgery, using a “watch and wait” approach. If it works, it may reduce the need for early surgery for carefully selected patients.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.